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Abstract: Background/Aim: This survey-based study aims to explore the clinical management protocols
of followed by Australian periodontists in relation to peri-implant diseases. Materials and Methods:
A five-part online questionnaire was developed and administered through email. Descriptive statistics
were used for analysis, with the univariate associations between a categorical outcome and the variables
evaluated using Pearson’s Chi-squared test. Results: The survey yielded 99 responses, resulting in a
response rate of 41.8%. Most participants were male and aged 35–44 years. More than a quarter of
practitioners had been placing implants for 6–10 years and almost two-fifths of practitioners placed
1–10 implants per month. The estimated prevalence of peri-implant mucositis and peri-implantitis
in the general Australian population was 47% and 21%, respectively. Practitioners reported using
systemic antibiotics to manage peri-implant mucositis (7%) and (72%) peri-implantitis lesions, with
a combination of amoxicillin and metronidazole. Most common treatment modalities were oral
hygiene instructions, nonsurgical debridement and antimicrobial gel/rinse. Surgical debridement
and systemic antibiotics were also often used for peri-implantitis treatment. Practitioners preferred
a 3-month clinical follow-up and 6-month radiographic evaluation. Furthermore, three-quarters
of practitioners rated their management as moderately effective, although upwards of nine-tenths
expressed the need for further training and awareness. Conclusion: This study confirms a significant
use of empirical treatment modalities due to lack of standard therapeutic protocol. However, some
approaches followed by the specialists may provide a basis to formulate a therapeutic protocol for
peri-implant disease management.
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1. Introduction
The advent of osseointegrated dental implants has revolutionised the treatment of edentulous
patients over the past four decades [1–5]. High success rates that dental implant therapy achieves in
various clinical situations has resulted in implant survival rate of 82.6% up to 15 years [4]. Despite
this, dental implants are still subject to several complications which can compromise this high success
rate [1–4]. Adler et al. reports that biological complications are the most common complication,
responsible for over half (52%) of all encountered complications [4]. These complications include peri-
implant mucositis and peri-implantitis, both of which are inflammatory diseases associated with the
placement of dental implants [1–4,6,7].
In 2017, the ‘World Workshop on Periodontology’ (WWP) defined peri-implant mucositis as “an
inflammatory lesion of the soft tissues surrounding an endosseous implant, in the absence of loss of
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supporting bone or continuing marginal bone loss [6].” Further, peri-implantitis was defined as “a
pathological condition occurring in tissues around dental implants, characterized by inflammation in
the peri-implant connective tissue and progressive loss of supportive bone [7].”
Prevalence of peri-implant mucositis has been reported to be close to 47% whilst peri-implantitis
occurred in 20% of implant patients [8]. Prevention and successful treatment of peri-implant diseases
relies on a thorough understanding of the aetiological factors implicated in the pathological condition.
A definitive cause-and-effect relationship between bacterial biofilms and peri-implant mucositis has
been long established [6]. This is critical as peri-implant mucositis is considered a precursor for peri-
implantitis, although the histopathologic and clinical conditions driving this progression are not yet
completely understood [6,7]. In addition to bacterial accumulation, several other aetiological factors
and risk indicators have been identified in relation to peri-implant diseases, including, poor oral
hygiene, history of periodontitis, excess cement, smoking, systemic conditions (i.e., diabetes mellitus),
absence of keratinized mucosa, improper design of implant-supported restorations and occlusal
overloading [6,7,9].
Despite a growing knowledge base around peri-implant pathologies, the treatment of such
conditions remains a clinical challenge. This is primarily due to the lack of evidence-based guidelines
available to clinicians in utilising different treatment modalities. Currently, a gold-standard therapeutic
protocol for peri-implant pathological lesions does not exist [10–13].
Dental implant treatment has risen significantly worldwide over the last few decades, with
Australia being described as a “fast expanding market” [6]. Guo et al. also noted that an increasing
proportion of dental implant treatment is being carried out by general dental practitioners, so much so
that they predicted that “implant dentistry will become a significant part of contemporary general
dental practice in the foreseeable future” [6]. Prevalence of peri-implant pathologies has also been
shown to be positively correlated with the duration for which the implant is in function [8]. Based on
both these factors, it can be projected that biological failures will further affect implant success rates in
Australia in the near future.
In 2009, Mattheos et al. surveyed and compared Australian periodontists to British periodontists
in relation to their management decisions and attitudes towards peri-implantitis [2]. Their study
concluded that neither country had a universal approach to managing peri-implant pathologies, with
significant heterogeneity being reported [2]. Similar heterogeneity was reported when comparable
studies were conducted in Sweden [14] and the United States of America [1] (USA).
With an ever-increasing number of implants being used to rehabilitate patients in Australia
and those implants being functional units for a greater number of years, it is imperative that a
well-defined evidence-based clinical protocol needs to be adopted so as to guide clinicians treating
biological complications of implant therapy. In recent years, there has been a concerted effort to increase
understanding of peri-implant pathologies, including definitions and diagnostic tools [3,6,7].
This study was conducted to investigate the perceived prevalence along with the aetiological
factors for peri-implant pathologies, and to investigate the therapeutic protocols most commonly used
to manage these conditions by Australian periodontists.
2. Materials and Methods
This study has been conducted in accordance with the STROBE guidelines for the presentation of
cross-sectional studies [15]. Ethical approval for the study was obtained from James Cook University’s
human research ethics committee (HREC Approval #H7701, 24 April 2019). The study was conducted
in Australia, with convenience sampling used to recruit Australian periodontists. Information about
practices with periodontists was obtained from public domain websites and this information was further
verified through telephone conversation. The surveys were created electronically using SurveyMonkeyTM
(San Mateo, CA, USA) and administered through email links sent to the participating practices. Although
all Australian periodontists were invited to participate in this study, the information page at the beginning
of the survey explicitly stated that the participation was voluntary and completion of the survey implied
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consent. The survey could only be filled out once by each participating periodontist. All collected survey
data was treated as confidential and anonymous. Data collection was completed between November
2019 and February 2020. Inclusion criteria included all periodontists currently registered with the
Australian Health Practitioner Regulation Agency (AHPRA) and actively practicing as a periodontist in
Australia. Exclusion criteria included those without registration or not actively practicing.
2.1. Questionnaire Design
A five-part questionnaire was developed based on previously validated and published surveys
in Australia [2], Sweden [14] and the USA [1]. The five sections within the questionnaire included
demographics; implant history; prevalence and aetiology of peri-implant diseases; treatment and
management of peri-implant diseases; training and education surrounding peri-implant disease. This
survey was validated in its online format by two prominent Australian periodontists associated with
post-graduate dental schools in Australia (University of Queensland and University of Sydney). Most
questions were close-ended multiple choice questions, with an option for open-ended responses where
appropriate. Other response types included a sliding percentage scale (0–100) and a ranking matrix
which required practitioners to grade options from most common to least. The survey consisted of 26
questions in total and took an average of seven minutes to complete.
2.2. Statistical Analyses
According to the Dental Board of Australia’s December 2019 registration data table, there were 237
registered periodontists in Australia. Based on this figure, a required sample size of 93 periodontists
was calculated, accounting for a 95% confidence interval, estimated portion of 50% and an 8% margin
of error. Descriptive statistics (counts and percentages) were primarily used for analysis. Pearson’s
chi-squared test (χ2) was used to evaluate univariate associations between categorical outcomes and
other variables. Statistical significance was set at p-values < 0.05, with a 95% confidence interval (CI).
SPSS IBM Statistics version 25 for Windows package (Chicago IL, USA) was used to analyse the data.
3. Results
Of the 237 registered periodontists in Australia, 108 responded to the survey. Of these 108
responses, 99 practitioners completed the entire survey, resulting in a completion rate of 91.7% and a
response rate of 41.8%. Data collected from 8 practitioners who failed to complete the survey were
excluded from the analysis.
3.1. Demographics
Most respondents in this study identified as male (73.7%) and were aged 35 to 44 years (48.5%).
Most practitioners completed their periodontal training from either the University of Melbourne
(29.3%) or the University of Queensland (28.3%). A little more than a quarter of practitioners had
been practicing periodontists for 6–10 years (27.3%), while a little less than a quarter had done it for
11–15 years (24.2%) (Table 1).
3.2. Implant History
All but 2 practitioners reported that they placed dental implants (98%), with more than a quarter
doing so for 11–15 years (28.9%). Almost three-quarters of practitioners reported that they placed
either 1–10 implants (38.5%) or 11–20 implants (36.5%) on average per month. A significant association
was found between increased years placing implants to implants placed/month (χ2 = 37.894, df = 16,
p = 0.002) (Table 1).
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Table 1. Practitioners’ Demographics and Implant History.





26–34 years old 1 1.01
35–44 years old 48 48.48
45–54 years old 18 18.18
55–64 years old 27 27.27
Over 65 years 5 5.05
Post-Graduate Education
Griffith University 6 6.06
University of Adelaide 12 12.12
University of Melbourne 29 29.29
University of Queensland 28 28.28
University of Sydney 11 11.11
University of Western Australia 9 9.09
Outside Australia 4 4.04
Periodontist Experience
2–5 years 8 8.08
6–10 years 27 27.27
11–15 years 24 24.24
16–20 years 15 15.15
21–25 years 6 6.06
26–30 years 12 12.12
31–35 years 3 3.03





1–5 years 4 4.12
6–10 years 23 23.71
11–15 years 28 28.87
15–20 years 18 18.56








3.3. Prevalence and Aetiology of Peri-Implant Diseases
Each periodontist was asked to estimate the percentage of peri-implant mucositis and
peri-implantitis amongst their patients and the general Australian population on a percentage scale of
0–100. Periodontists predicted that approximately 36% and 14% of their own patients suffer from peri-
implant mucositis and peri-implantitis, respectively. They also predicted that the corresponding figures
in the general Australian population were 47% and 21%, respectively. Furthermore, practitioners
estimated that 12% of implants eventually need to be removed due to peri-implantitis (Figure 1).
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Figure 1. Estimated Prevalence of Peri-implant Diseases in the Australian population.
Subsequently, practitioners were then asked to rank eight aetiological factors from most likely
to contribute towards peri-implant pathology to least likely. All factors were then given a weighted
average score out of 8 (higher meaning more commonly chosen). The three most commonly chosen
factors were bacterial plaque accumulation (7.06), history of periodontitis (6.42) and smoking (5.37)
(Figure 2 and Table 2).
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Table 2. Aetiological Factor Ranking: weighted score out of 8 (higher = more commonly chosen).
Aetiological Factor/Rank 1 2 3 4 5 6 7 8 N/A WeightedScore (8)
Bacterial plaque due to poor oral hygiene 56.12% 18.37% 15.31% 3.06% 4.08% 1.02% 0% 2.04% 0% 7.06
Adverse loading/Parafunction 2.04% 3.06% 0% 6.12% 10.20% 18.37% 12.24% 40.82% 7.14% 2.47
Smoking 7.14% 21.43% 27.55% 11.22% 14.29% 14.29% 4.08% 0% 0% 5.37
History of Periodontitis 29.59% 28.57% 16.33% 15.31% 4.08% 4.08% 0% 2.04% 0% 6.42
Excessive Cement 3.03% 13.13% 8.08% 15.15% 28.28% 16.16% 12.12% 4.04% 0% 4.30
Inadequate band of keratinised tissue 2.04% 0% 0% 11.22% 12.24% 12.24% 36.73% 23.47% 2.04% 2.60
Patient’s systemic health 0% 5.05% 20.20% 20.20% 13.13% 18.13% 19.19% 4.04% 0% 4.07
Improper design of restoration 0% 10.10% 12.12% 18.18% 14.14% 14.14% 16.16% 13.13% 2.02% 3.87
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3.4. Management of Peri-Implant Diseases
Concerning post-operative systemic antibiotics, practitioners stated that they would use them
for 7% and 72% of peri-implant mucositis and peri-implantitis cases, respectively. Amoxicillin and
Metronidazole combination was the most commonly selected antibiotic(s) that was utilised as first-line
management for peri-implant diseases (41.8%), followed by azithromycin (26.5%) (Table 3). A significant
association was found between practitioners who chose the combination amoxicillin and metronidazole
and those who had been placing implants for over 20 years (χ2 = 56.842, df = 20, p < 0.001), as well as
those who placed more than 50 implants/month (χ2 = 35.900, df = 20, p = 0.016).
Table 3. Practitioners’ Clinical Management of Peri-Implant Diseases.
Frequency (n) Percentage (%)
Antibiotic Choice
Amoxicillin 21 21.43
Amoxicillin + Clavulanic Acid 3 3.06




Every 3 months 55 56.12
Every 6 months 37 37.76
Every 12 months 1 1.02
Radiographic Evaluation
Immediately 5 5.05
3 months 10 10.10
6 months 56 56.57
9 months 2 2.02
12 months 22 22.22
Practitioners were also asked to rank the frequency of (always, often, sometimes, rarely or never)
various proposed treatment modalities for peri-implant pathology. These modalities were then assigned
a numerical value (ranging from 1 through to 5) to determine the most commonly chosen treatment
protocols. The three most commonly chosen treatment modalities for peri-implant mucositis were
oral hygiene instructions (1.02), nonsurgical debridement (1.17) and antimicrobial gel/rinse (2.06). All
other modalities received scores between 4 and 5, suggesting that they were rarely-to-never used to
treat peri-implant mucositis. Regarding treatment of peri-implantitis, oral hygiene instructions (1.06),
antimicrobial gel/rinse (1.59) and nonsurgical debridement (1.86) were still the three most commonly
chosen responses, although the other options were not so uncommon. Systemic antibiotics (1.92),
surgical debridement (2.42), surgical resective therapy (2.76) and surgical regenerative therapy (2.97)
all received scores around 2–3, suggesting that they were used often or sometimes (Figures 3 and 4 +
Tables 4 and 5).
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Table 4. Peri-implant Mucositis Treatment Modalities: Average Frequency (Always (1) through to Never (5)).
Frequency/Therapeutic Modality Always (1) Often (2) Sometimes (3) Rarely (4) Never (5) Average Frequency (1–5)
Oral Hygiene Instructions 97.98% 2.02% 0% 0% 0% 1.02
Antimicrobial gel/rinse 43.16% 23.16% 23.16% 5.26% 5.26% 2.06
Nonsurgical debridement 88.89% 8.08% 0% 3.03% 0% 1.17
Surgical debridement (access only) 0% 4.49% 12.36% 23.60% 59.55% 4.38
Surgical resective therapy 0% 0% 5.43% 8.70% 85.87% 4.80
Surgical regenerative therapy 1.11% 0% 0% 10.00% 88.89% 4.86
Systemic Antibiotic 0% 0% 14.13% 22.83% 63.04% 4.49
Control of Occlusion 0% 10.87% 22.83% 11.96% 54.35% 4.10
Table 5. Peri-implantitis Treatment Modalities: Average Frequency (Always (1) through to Never (5)).
Frequency/Therapeutic Modality Always (1) Often (2) Sometimes (3) Rarely (4) Never (5) Average Frequency (1–5)
Oral Hygiene Instructions 97.96% 0% 0% 2.04% 0% 1.06
Antimicrobial gel/rinse 60.00% 27.37% 6.32% 6.32% 0% 1.59
Nonsurgical debridement 58.33% 18.75% 2.08% 19.79% 1.04% 1.86
Surgical debridement (access only) 13.27% 51.02% 21.43% 9.18% 5.10% 2.42
Surgical resective therapy 4.21% 44.21% 27.37% 20% 4.21% 2.76
Surgical regenerative therapy 2.08% 39.58% 27.08% 21.88% 9.38% 2.97
Systemic Antibiotic 43.88% 30.61% 19.39% 2.04% 4.08% 1.92
Control of Occlusion 12.77% 15.96% 20.21% 38.30% 12.77% 3.22
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Details on the instrumentation used for the debridement of implant surfaces in peri-implant
diseases were sought through a rank question, in which a weighted score was determined out of 9
(Higher meaning more commonly used). The three most commonly chosen instruments/devices were
ultrasonic scaler (8.02), air abrasive device (7.29) and a titanium scaler (7.12) (Figure 5 and Table 6).
Similarly, practitioners were requested to rank the regenerative materials they used to treat peri-implant
diseases and a weighted score out of 8 was calculated. The three most commonly chosen regenerative
materials were resorbable GTR (guided tissue regeneration) membrane (7.11), xenograft (6.90) and
growth factors (5.47) (Figure 6 and Table 7).
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Table 6. Debridement instrumentation/devices ranking: weighted score out of 9 (higher = more commonly chosen).
Instrumentation/Rank 1 2 3 4 5 6 7 8 9 N/A WeightedScore (9)
Ultrasonic Scaler 40.40% 33.33% 6.06% 11.11% 1.01% 0% 0% 0% 1.01% 7.07% 8.02
Titanium Scaler 19.39% 15.31% 10.20% 10.20% 8.16% 5.10% 1.02% 0% 0% 30.61% 7.12
Plastic Scaler 3.03% 4.04% 16.16% 16.16% 14.14% 3.03% 0% 0% 0% 43.43% 6.23
Stainless Steel Instruments 3.03% 19.19% 23.23% 17.17% 17.17% 0% 1.01% 0% 0% 19.19% 6.63
Er:YAG Laser 0% 2.06% 1.03% 0% 4.12% 6.19% 5.15% 5.15% 2.06% 74.23% 3.76
Air Abrasive Device 32.32% 9.09% 12.12% 8.08% 5.05% 4.04% 4.04% 1.01% 0% 24.24% 7.29
Sonic Scaler 0% 7.14% 5.10% 3.06% 2.04% 9.18% 10.20% 0% 0% 63.27% 5.14
Diode Laser 0% 0% 5.10% 2.04% 1.02% 5.10% 2.04% 15.31% 5.10% 64.29% 3.23
Titanium Brush 0% 9.18% 14.29% 7.14% 7.14% 10.20% 4.08% 0% 5.10% 42.86% 5.43
Table 7. Regenerative materials ranking: weighted score out of 8 (higher = more commonly chosen).
Regenerative Material/Rank 1 2 3 4 5 6 7 8 N/A WeightedScore (8)
Resorbable GTR Membrane 41.05% 29.47% 13.68% 0% 4.21% 0% 1.05% 0% 10.53% 7.11
Nonresorbable GTR Membrane 0% 1.10% 1.10% 10.99% 4.40% 6.59% 7.69% 1.10% 67.03% 3.73
Growth Factors 0% 12.90% 11.83% 11.83% 8.60% 3.23% 0% 0% 51.61% 5.47
Xenograft 45.26% 20.00% 9.47% 0% 0% 3.16% 0% 5.26% 16.84% 6.90
Allograft 3.19% 10.64% 10.64% 7.45% 3.19% 4.26% 9.57% 0% 51.06% 5.02
Autograft 2.20% 8.79% 12.09% 9.89% 12.09% 13.19% 0% 0% 41.76% 4.96
Connective Tissue Grafting 2.11% 11.58% 27.37% 31.58% 8.42% 2.11% 3.16% 1.05% 12.63% 5.35
Do Not Use Regenerative Surgery 6.45% 0% 0% 5.38% 3.23% 0% 5.38% 3.23% 76.34% 4.45
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Regarding follow-up visits, most practitioners stated that a patient who has been successfully
treated for peri-implant disease should be seen every 3 months (56.1%) or 6 months (37.8%). There was
no significant association found between choice of follow-up visits and either years placing implants
(χ2 = 9.907, df = 12, p = 0.607) or number of implants placed per month (χ2 = 16.884, df = 12, p = 0.155).
Most practitioners would wait 6 months after successful treatment before conducting a radiographic
evaluation of the treated site (56.6%). Practitioners who had greater experience with implants, through
both years placing them (χ2 = 46.73, df = 20, p = 0.001) and implants placed/month (χ2 = 63.587, df = 20,
p < 0.001) were significantly more likely to report a longer radiographic evaluation period of 12 months
(Table 3).
3.5. Training and Education Surrounding Peri-Implant Disease
More than three-quarters of practitioners opined that their current management of peri-implant
disease was moderately effective (76.8%) and almost all practitioners (96.0%) had updated their training
in this field within the last 2 years. Although there was no significant association between years
placing implants (χ2 = 12.145, df = 8, p = 0.162) and self-assessment of effectiveness, those who placed
more implants/month (χ2 = 26.326, df = 8, p = 0.030) were significantly more likely to report that their
management was only mildly effective as opposed to moderately effective. Practitioners who had been
placing implants for 11–15 years (χ2 = 18.311, df = 4, p = 0.008) and those placing 21–30 implants/month
(χ2 = 19.396, df = 4, p = 0.004) were significantly more likely to report that they hadn’t updated
their training in this area in the last two years. Despite this, more than nine-tenths of practitioners
(90.9%) expressed that there should be increased training and awareness surrounding management of
peri-implant disease. (Table 8) While implants placed/month (χ2 = 8.407, df = 4, p = 0.073) did not have
a significant impact on increasing awareness, those who had been placing implants for 11–15 years
(χ2 = 24.447, df = 4, p = 0.001) were more likely to report that increased awareness in this field was
not required.
Table 8. Practitioners’ Attitude Towards Training.
Efficacy of Current Management
Ineffective 0 0
Mildly effective 21 21.21
Moderately effective 76 76.77
Very effective 2 2.02
Updated Training in Last 2 Years
Yes 95 95.96
No 4 4.04




Inconsistent definitions, lack of clear clinical parameters and various reporting methods have led to
variable reports on the prevalence of peri-implant diseases [16,17]. The definitions set out by the WWP
in 2017 clarified clinical cut-off points for peri-implant pathologies for both everyday clinical practice
and epidemiological studies [3,6,7,18]. Applying these parameters to the best of their ability, Cosgarea
et al. reported the prevalence of peri-implant mucositis to be 46.8% and peri-implantitis to be 18.5 [19]
and 19.83% [18] for peri-implantitis [20]. In this study, Australian periodontists reported a disease
prevalence of 47% and 21% for peri-implant mucositis and peri-implantitis, respectively. Although these
figures closely match those reported previously, [20] practitioners believed that the disease prevalence
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in their own patients was significantly lower, at 36% and 14% respectively. Papathanasiou et al. also
found that American periodontists felt that the general population had a higher disease prevalence than
their own patients. They attributed this finding to possible psychologic factors and response bias [1].
This discrepancy may also be due to perceived differences in definition of peri-implant disease between
epidemiological studies and practitioners in their clinical settings.
Dental Implant therapy is associated with a high success rate and this has been reported by several
authors, [1–5] including Adler et al. who reported a cumulative implant survival rate of 82.6% over
a 9–15-year follow-up period [4]. Patients in the study conducted by Adler et al. underwent dental
therapy in Stockholm, Sweden (1999–2005) [4]. Participants in this study estimated that approximately
12% of implants needed to be removed due to peri-implantitis in the Australian population. While
biological complications are most prevalent, there are other complications which can further affect
the implant survival rate. Accounting for other complications, Australian periodontists seem to be
experiencing similar cumulative implant survival rates as that reported by Adler et al. [4].
In the 2017 WWP, Heitz-Mayfield et al. [6] and Schwarz et al. [7] elaborated on potential
risk factors/indicators with substantial evidence for peri-implant diseases. These included poor
plaque control, history of periodontitis, smoking and diabetes. In the current study, Australian
periodontists identified bacterial plaque, history of periodontitis and smoking as the three most
significant aetiological/predisposing factors behind peri-implant pathology. Several cross-sectional
studies have demonstrated that biofilm accumulation is associated with the development of peri-implant
mucositis lesions [21–23]. Roos-Jansaker et al. studied 218 patients with 999 implants in function over
a period of 9- to-14 years, reporting a significant association between plaque scores and peri-implant
mucositis [22]. The progression from peri-implant mucositis to peri-implantitis has been explored in
numerous studies [24,25]. Costa et al. conducted a retrospective study of 80 patients initially suffering
from peri- implant mucositis. Over a five-year period, they found that the incidence of peri-implantitis
was lower (18%) in subjects enrolled in a regular maintenance program than those without (43%) [25].
Roccuzzo et al., [26] Monje et al. [27] and Kassebaum et al. [28] reported that patients who complied to
a regular maintenance therapy following implant therapy were significantly less likely to be diagnosed
with peri- implantitis, over a period of 10 years, 2 years and 3.8 years, respectively.
Periodontitis is one of the most prevalent diseases in the world, [28] and it has been found
to be associated with peri-implantitis. Karoussis et al. [29] and Roccuzzo et al. [26,30] conducted
10-year longitudinal studies, finding that peri-implantitis incidence in individuals with a history of
periodontitis was significantly higher. Roccuzzo et al. also reported that treatment of peri-implantitis
was more time-consuming in such patients [26,30].
It has been well established that smoking is strongly associated with periodontitis, attachment loss
and tooth loss [7]. It is thought that this effect translates to peri-implant tissues as well. Karoussis et al.
found that 18% of all implants in smokers developed peri-implantitis, compared to 6% in nonsmokers,
over a period of ten years [29]. However, several cross-sectional studies have also reported that
smokers are not at higher risk for developing peri-implantitis [31–33]. These could potentially be due
to confounding factors, but nonetheless, Schwarz et al. concluded that there is currently no conclusive
evidence that smoking constitutes a risk factor for peri-implantitis [7].
In 2011, Mombelli et al. conducted a review in which they concluded that the combination
of metronidazole and amoxicillin has the potential to overcome a wide range of pathogens often
associated with peri-implant disease [34]. Amoxicillin, [35] metronidazole [36] and azithromycin [37]
have all proven to be useful adjuncts in the treatment of peri-implant disease [12]. Despite their
short-term efficacy, there does not appear to be strong evidence that these effects are sustained in the
longer term, [38] and antimicrobial resistance has also been detected in peri-implant biofilms [39]. The
combination of amoxicillin and metronidazole was the most commonly chosen first-choice antibiotic
regimen amongst Australian periodontists in this study, particularly amongst those who had been
placing implants for more than 20 years or 50+ implants/year.
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Practitioners in this study found that oral hygiene instructions, nonsurgical debridement and
antimicrobial gel/rinse were effective enough treatment modalities to counter peri-implant mucositis.
This notion was supported by Derks et al. who concluded that nonsurgical approaches with thorough
mechanical debridement appear to be effective approach for peri-implant mucositis, but outcomes are
more guarded in the management of peri-implantitis [16]. Interestingly, Australian periodontists in
our study, were increasingly likely to use surgical approaches and systemic antibiotics to treat peri-
implantitis lesions. This may be due to the fact that while nonsurgical treatment is still often performed
as part of initial therapy, it has been reported to only be moderately effective in the management of
peri-implantitis [40,41]. Surgical techniques offer more predictable outcomes, [42] through improved
access and the possibility for resective and regenerative procedures, [43] with several studies reporting
positive outcomes [44,45]. Australian periodontists report using surgical techniques often—sometimes
to manage peri-implantitis lesions.
Several instruments have been used to debride affected implant surfaces in both surgical and
nonsurgical approaches [46]. Ultrasonic devices and titanium curettes [11] have been favoured among
UK [2] and American periodontists, [1] in line with Australian periodontists. Air-abrasive devices
are also popular amongst Australian periodontists, although there is little evidence supporting their
enhanced cleaning efficacy in the long term, as compared to other instruments [47,48]. Surgical
regenerative therapy was the least likely treatment protocol used by periodontists treating peri-implant
lesions and is rarely utilised by Australian periodontists. Amongst those that use surgical approaches
for management of peri-implantitis lesions, the most common regenerative procedure employed was
GTR membrane alone, despite some studies demonstrating minimal benefit of barrier membranes
when compared to bone-grafting alone [49,50].
Supportive maintenance therapy with regular reviews is essential for all patients treated for peri-
implant disease [13] with most Australian periodontists considering a 3-month follow-up as most
preferred. A majority of practitioners conducted a radiographic evaluation of the treated site 6- months
after treatment. Practitioners with greater experience through years placing implants and implants
placed/month were more likely to conduct a radiographic evaluation at 12 months, suggesting that
6 months may be too early to expect radiographic changes in the treated site. Papathanasiou et al.
reported similar findings in America, where the majority of practitioners also reported 3-month follow
ups and a 6-month radiograph, although they found that less experienced practitioners were more
likely to conduct a radiographic evaluation sooner than 6 months [1].
Although more than three-quarters of practitioners in this study rated their management of peri-
implant diseases as moderately effective, it was found that those placing more implants/month were
significantly more likely to report their management as mildly effective. The increase in implants
placed likely leads to an increase in the number of failures seen, particularly peri-implant diseases, and
conditions of varying severity may lead these clinicians to be more cautious in their self- assessment.
All but four practitioners reporting that they had updated their training around peri- implant pathology
in the last two years and upwards of 90% of practitioners suggested that greater awareness surrounding
the management of peri-implant disease is warranted. These figures reflect the continuing uncertainty
in this field, with a gold standard management protocol yet to be established, [10–13] with one
participant aptly stating that “unfortunately, most of the research just tells us what doesn’t work.”
While this study has shed light on an increasingly important matter, it does have its limitations,
particularly due to its response rate. Although it has a higher response rate than similar studies in
the USA [1] and the UK, [2] it still falls short of 50% of all eligible periodontists in Australia. While
this remains a significant barrier, this study has utilised other means to improve the quality of data,
including the use of an electronic format. The electronic format has enabled the collection of accurate
and versatile data, with precise prevalence percentages along with a ranking system for aetiology,
treatment and instrumentation reported as weighted scores. This electronic format coupled with clear
definitions and clinical parameters in accordance with the 2017 WWP have enabled the creation of
reliable baseline data for future research in this field.
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5. Conclusions
This study demonstrates that Australian periodontists acknowledge the increasing prevalence
of peri-implant diseases and frequently deal with them in their routine practice. Although most
periodontists agreed that the most common aetiological factor behind peri-implant diseases is bacterial
accumulation, there was significant heterogeneity regarding treatment protocols. Due to the lack of a
standard therapeutic protocol, there appears to be significant empirical use of therapeutic modalities.
Despite this, most periodontists believe that their management is moderately effective and continue to
update their training regularly. These results allow general dental practitioners to consider various
approaches employed by periodontists in management of peri-implant diseases and scaffold their
treatment approaches. Future studies elaborating on successful treatment protocols are needed as they
become widely accepted and adopted by periodontists.
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